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ABSTRACT
Objective: A process capability study is a formal procedure for undertaking a systematic investigation to reliably assess a process ability to consistently 
meet a specific requirement. Its indices are to measure the inherent variability of a process and thus to reflect its performance. This study describes 
the evaluation of process capability in the manufacture of antihypertensive tablets 10 mg.
Methods: This project focuses on process capability study that had been applied in the Pharmaceutical industry which includes selection of critical 
parameters, data collection, study on process capability, and data evaluation. In this process capability study, the critical process parameters were 
identified and evaluated by challenging its lower and upper release specifications. Here, many statistical process control tools along with Minitab-16 
software were used to find the capability of this manufacturing process.
Results and Discussion: The discovered results for Ppk (Process performance index), tolerance limit and Standard deviation (overall) are 2.25, 40 
and 2.949, which advocates that the process meets the criteria required for capability. Process capability ensures that processes are fit for industry 
company specification while reducing the process variation and important in achieving product quality characteristic. This capability study should 
be employed in the industry before the batch is made commercial. It acts as a cost-effective approach that can reduce the time taken for inspection.
Conclusion: In this research work, the current capability of the process is predicted, and the process is found to be capable.
Keywords: Process capability, Specifications, Critical parameters.
INTRODUCTION
A plethora of process capability study in the pharmaceutical industry 
has been proposed recently and represented in the International 
Organization for Standardization/International Electro technical 
Commission (ISO/IEC) ISO 22514 which is a suite of standards 
for statistical methods in process management - capability and 
performance of measurement processes. This international standard 
was developed by an ISO software engineering working group 
established by the ISO and the IEC in 2012 [1-3]. A process capability 
study is a formal procedure for undertaking a systematic investigation 
to reliably assess a process ability to consistently meet a specific 
requirement. A process capability index defined as a quantitative way 
to express process variability. One-way of evaluating process capability 
study was conducted using Minitab-16 software [3].
Process capability analysis in pharmaceutical production
A pharmaceutical company produces products such as tablets, 
capsules as per customer requirements. Customer requirements are 
the significant features that the customers expect to find in a product. 
Development scientists translate those requirements into “critical-to-
quality” (CTQ) characteristics of the products that they are about to 
produce. As example, hardness, thickness, uniformity of weight, assay, 
dissolution, etc., are CTQ characteristics of tablets [4]. When these 
CTQ characteristics are assessed and quality targets are determined, 
development scientists specify upper and lower limit within which 
variables of CTQ characteristics must fall. To evaluate production 
process performance, the CTQ characteristics are monitored when 
production in progress. A control chart is one of the tools which used 
to monitor the characteristics [5]. We can see whether the data of CTQ 
characteristics are within limit or not from control chart. Even if all the 
monitored data are within set limit, there is a possibility to produce a 
defective product. The tool by which we can say the process is capable 
to produce product complying customer’s requirements is process 
capability index Cpk [6].
Hierarchy of process capability
The hierarchy of process capability is explained by Statistical process 
control tool where it  is classified into Descriptive statistics, Process 
control and acceptance sampling.
The various tools are classified in Fig 1.
Simple view of process control and process capability [7-9]
Process capability can never be divorced from concepts of control 
charts that W.A. Shewhart envisaged. The capability of a process is 
independent of any specifications that may be applied to it. It is basic to 
the process and may be thought of as inherent process capability. This 
capability can be estimated from a range or standard deviation chart 
on past data but it can be measured only when the process itself is in 
control.
•	 Process	control	refers	only	to	the	“voice	of	the	process,”	looking	at	
the process using an agreed performance measure to see whether 
the process forms a stable distribution over time.
•	 Process	capability	measures	the	“goodness	of	a	process,”	comparing	
the voice of the process with the “voice of the customer.” The voice 
of	 the	customer	here	 is	 the	specification	range	(tolerance)	or	 the	
nearest	customer	specification	limit.
Why is a process capability study done? [10]
1.	 To	assess	the	potential	capability	of	a	process	at	a	specific	point	or	
points	in	time	to	obtain	values	within	a	specification,
2. To predict the future potential of a process in order to create a value 
within	specification	with	the	use	of	meaning	metrics,	and
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3. To identify improvement opportunities in the process by reducing 
or possibly eliminating sources of variability.
4. Process capability Vs Process Performance is explained in Table 1.
There are three conditions that must be satisfied to make process 
capability and performance statistics meaningful metrics:
1. The sample must be truly representative of the process. This includes 
the 6M’s: Man, machine, material, measurements, methods, and 
mother nature (environmental).
2. The distribution of the quality characteristic must be Gaussian, 
i.e., the data can be normally distributed in a probability curve. If 
the data does not conform, the question is: Can it be normalized? 
Various analytical methods are used to potentially normalize data 
or apply a non-parametric analysis like box-cox transformation, Log 
transformation, Weibull Method, etc.
3. The process must be in statistical control. In other words, is it a 
stable and its variation generally random (common cause)? Note: 
A real-time control chart should be verifying statistical stability as 
process capability data is captured [11].
Do not wait until the data is taken to create a control chart, only to 
discover that the process trended out of statistical control along the 
way or had some other identifiable problem.
MATERIALS AND METHODS
Materials
Table 2 was the materials used to carry out the study.
The Equipments used during Process and source are given below in 
Table 3.
Equipment used during In-Process checks is given below in Table 4.
Software used in process capability study is Given below in Table 5
Methods [12-14]
Brief description on manufacturing process of antihypertensive 
tablets
During all stages of the manufacturing process, temperature and 
humidity should be NMT 25 C and NMT 45% RH, respectively. The 
stages involved in the manufacturing process were as follows.
Dispensing
Raw materials used in the manufacturing were procured from 
the approved vendors met the specifications laid down. All raw 
materials should be dispensed in dispensing area of warehouse under 
contamination control station as mentioned in Batch manufacturing 
Table 1: Process capability versus process performance
Process capability Process performance
Process capability requires that the standard deviation estimate 
come from subgroups of data (rational subgroups where variation 
within them is considered homogenous)
This means that the variation overtime will exist between the 
subgroups but that the variation is homogenous within the 
subgroup. A control chart will be used to show the assignable cause 
variation that is present in the process.
Process performance requires that the standard deviation estimate 
come from the overall data set. This means that there is no component 
involved in this long term estimate of the standard deviation; hence all 
the sources of variations are combined
A histogram, stem and leaf plot, dot plot or similar graphic will show the 
shape of the overall data, whereas on time line there will be information 
on the assignable cause, variation present
Cp and Cpk are the process capability indices Pp and Ppk are the process performance indices
Table 2: Raw materials used in formulation of tablets
Ingredients Category Grade Source
Anti-hypertensive 
drug
API USP Hetero drugs, 
Hyderabad, India
Ingredient I Filter I NF FMC Bio polymers, 
Bangalore, India
Ingredient 2 Filter I USP Prayon, USA
Ingredient 3 Disintegrant NF Roquette, Mumbai, 
India
Ingredient 4 Lubricant NF Tyco, UK
Table 3: Equipment used during process









Octagonal blender Gansons Engineering PVT Ltd., Mumbai, 
India
Compression machine ACG PAM, Mumbai, India
Metal detection unit Techno Four Controls System, Mumbai, 
India
Tablet De-duster Techno Four Controls System, Mumbai, 
India
Table 4: Equipment used during in-process checks
Name of the equipment Source
Minitab 16
Table 5: Software used in process capability study
Name of the software used Version used
Electronic weighing balance Sartorius
Fig. 1: Hierarchy of process capability flow chart
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record (BMR). The dispensed raw materials were transferred to the 
manufacturing facility.
Milling
All the dispensed raw materials were milled using the Co-mill with 
speed between 1700 and 1900 RPM. Then milled materials were 
collected into stainless steel (SS) bins or containers. The mesh integrity 
and speed of mill before and after milling throughout the processing 
activity was checked. Finally, all the milled materials were transferred 
to mechanical sifter for sifting.
Sifting
The materials were sifted using mechanical sifter with appropriate 
sieve size. The antihypertensive drug and sodium starch glycolate were 
sifted using #60 and for microcrystalline cellulose, dibasic calcium 
phosphate (anhydrous), and magnesium stearate #40 was used. Finally, 
all the sifted materials were transferred to octagonal blender for the 
process of mixing.
Blending
The sifted materials were loaded into the octagonal blender (900 l) 
using vacuum conveying system except magnesium stearate. Blender 
was started and run in the inch mode to check for any leakage of 
materials. On ensuring that there was no leakage, blending was carried 
out for 15 minutes at 12 RPM. Magnesium stearate was mixed with 
the blend taken from blender after 15 minutes of initial blending time, 
and blending process was performed for 5 minutes. Finally, blend was 
unloaded into SS bins or containers.
Compression[15]
Compression was carried out as per the BMR. Compression machine 
was set up with punches and dies. The machine was set and operated at 
different speeds of 15-60 RPM. Powder blend was loaded into hopper 
and compression machine was set with parameters as specified in BMR 
and tablets were compressed. The speed of machine and powder level 
in hopper before and after compression was checked throughout the 
process.
Packing
Compressed tablets were packed in HDPE bottles in bulk packing line. 
Packing was done as per the batch packing records.
Process flow chart
Process flow chart during manufacturing process of antihypertensive 
tablets is explained according to the Checking of raw materials,weighing 
and dispensing.
The probability plot of Anti-hypertensive tablets 10mg is plotted in 
Fig 3 below.
The Selection of control charts based on data given below in Fig 4
RESULTS AND DISCUSSION
The results of the descriptive statistics were depicted in Table 6.









Upper control limit, UCLS	=	3.506
Lower control limit, LCLS	=	2.273
2. The results for the normal probability plot were follows:
AD	value	=	12.747
p<0.005
The results for the histogram were as follows:
Shape	of	the	histogram	=	Bell	shape
Highest frequencies were found at 401 and 400.
3. The results for the process capability indices were depicted in 
Table 7.
4. The results for the process performance indices were depicted in 
Table 8.
5. Figs. 5-8 are the summary reports of capability analysis obtained 
from Minitab software.
Fig. 2: Process flow chart during manufacturing process of 
antihypertensive tablets
Fig. 3: Probability plot of antihypertensive tablets 10 mg
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DISCUSSION
There were two critical assumptions to consider when performing 
process capability analyses with continuous data, namely:
1. The process in statistical control.
2. The distribution of the process considered as normal.
For statistical control process
The limits for the passing criteria as a statistical control for the points 
falling out of control in a process were given Table 9.
Fig. 4: Selection of control charts based on data
Fig. 5: Diagnostic report for capability analysis of 
antihypertensive tablets 10 mg
Table 6: Results for descriptive statistics
Descriptive statistics Results
Process average 399.902
Standard deviation (within) 2.897
Standard deviation (overall) 2.949
Process tolerance 40
Table 7: Results for the process capability indices





Table 8: Results for the process performance indices





Fig. 6: Process performance report for capability analysis of 
antihypertensive tablets 10 mg
 Raj et al. 




So it’s concluded that the process was in statistical control as per the 
X-bar chart.
B. In S chart, the control limits 2 points were falling out of control out of 
2500 observations. But from the above table, it indicates the process 
is in statistical control.
C. Distribution of the process:
From the normal probability plot graph in Fig. 2, the 
Anderson-Darling (AD) normality test shows that we should reject 
the null hypothesis, H0: Data follow a Normal distribution vs. H1: 
Data	 do	not	 follow	 a	 normal	 distribution,	 at	 the	 α=0.05	 significance	
level. This is due to the fact that the p-value for the A-D test is <0.05 
and	 AD	 value	 =	 12.747.	 This	 indicated	 the	 data	 was	 a	 non-normal	
distribution.
When the data were non-normal, we can find the process capability 
and process performance indices either by transforming data to a 
normal data through various transformation processes or directly as 
non-normal distribution Parameters to be considered to determine 
process capability based on the type of distribution were portrayed 
in Table 10.
Fig. 7: Summary report for capability analysis of antihypertensive 
tablets 10 mg











In non-normal for the process to be capable the following two conditions 
must be satisfied:
i. The standard deviation S must be <1/8th of the tolerance. In this 




ii. Ppk must be >1.33
Here	Ppk	=	2.25	which	is	>1.33.
Hence, we can consider that the second criterion was also passed for 
the test.
CONCLUSION
This study involved selection of critical quality characteristics, 
estimating the process capability indices of the process and interpreting 
the results to show that the process was under statistical control 
and capable. The study was conducted on a weight variation data of 
twenty-five batches. The overall manufacturing process was concluded 
as a capable process from the estimated process capability indices in 
the Minitab 16 software. The results of different descriptive statistics 
reveal that there was no significant variation between batches. From 
the values of the capability indices and report card of the study, we 
can conclude that process involved in the manufacturing of anti-
hypertensive tablets 10 mg stood capable.
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